ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
PU
Peking University People's Hospital at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Peking University People's Hospital takes part in 8 sessions at ESMO 2026 in Madrid. Its work spans treatment, tumor biology and early detection across several cancers. It reports a trial comparing risvutatug rezetecan with chemotherapy in osteosarcoma that has returned or resisted treatment.
| Organization | ESMO 2026 Attendance |
|---|---|
PU Peking University People's Hospital Beijing, China | |
Teaching hospital of Peking University Health Science Center in Beijing, China. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Profound vitamin D deficiency identifies elevated heart failure risk among breast cancer Survivors: A UK biobank multi-state analysis Breast cancerNursing & supportive care Poster Fri Oct 23 13:00–15:00 Abstract Sat Oct 24 08:50–09:00 Poster Sun Oct 25 12:00–12:45 Performance of an AI-based multi-cancer early detection (MCED) model in a Chinese multicenter cohort Biomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Immune microenvironment analysis of Ewing sarcoma identifies MIF-CD74 signaling Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Abstract Mon Oct 26 16:30–16:42 LBA9 - Risvutatug rezetecan (Ris-Rez) versus gemcitabine and docetaxel (GD) in heavily pretreated patients (pts) with relapsed or refractory (R/R) osteosarcoma: Primary results from the phase 3 ARTEMIS-011 study Gynaecological cancersSarcoma, CNS, head & neck and rare cancers |
Find decision makers at Peking University People's Hospital
Tell us what you sell and we’ll find the people at Peking University People's Hospital most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction